What should I look for in LL-37 sourcing and quality?

Acceptable LL-37 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 4493 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What is the evidence base for LL-37?

LL-37's evidence base sits at preclinical + small human series. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How long until I see results from LL-37?

Acute effects from LL-37 appear within the first week for downstream physiological adaptation. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the regulatory status of LL-37?

LL-37 regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level preclinical + small human series. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Home/ Compounds/ LL-37

LL-37

Protocol

Protocol design for LL-37 starts with pharmacokinetics and ends with calendar planning. The compound's Variable; tissue-localised half-life via subq/topical/nebulised administration places it in the daily-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.

Protocol / Scheduling / Cycling Applications

Wash-OutLoading PhaseTravel ConsiderationsCycle LengthMulti-Peptide Timing

Key Takeaways

Scheduling lens: LL-37's Variable; tissue-localised half-life via subq/topical/nebulised places it in the daily-dosing bucket.
Mechanism: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Protocol calendar planning for LL-37 is shaped by mechanism, pharmacokinetics, and operational reality. Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Disrupts microbial membranes electrostatically. Neutralises LPS. Modulates immune cell signalling via FPR2 and P2X7 receptors. Active against gram-positive, gram-negative, mycobacterial, and biofilm phenotypes. The subsections below work through the daily timing patterns, the 8-12 week cycle structure with calibrated off-period, the stack scheduling principles, and the travel-and-disruption playbook.

Stack scheduling with other compounds

When LL-37 is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any LL-37 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most LL-37 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

LL-37 with a Variable; tissue-localised half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either Daily SubQ for 4-8 weeks, with consistency mattering more than the absolute clock time of any single dose.

Protocol / Scheduling / Cycling Applications

Daily Timing

Schedule design for LL-37 in daily timing starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Cycle Length

The most-asked scheduling question for LL-37 in cycle length is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Loading Phase

For loading phase scheduling, LL-37 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Pulse Strategies

Schedule design for LL-37 in pulse strategies starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60-500 mcg	4–6 weeks initial cycle
Protocol focus	SubQ	100-500 mcg	Daily SubQ for 4-8 weeks
Maintenance phase	SubQ	70-500 mcg	Ongoing with periodic pauses

Dose timing for LL-37 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

LL-37 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

LL-37 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with LL-37's mechanism in protocol / scheduling / cycling protocols.
LL-37 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with LL-37's mechanism in protocol / scheduling / cycling protocols.
LL-37 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with LL-37's mechanism in protocol / scheduling / cycling protocols.
LL-37 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with LL-37's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Preclinical + small human series

Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions.

Lens-specific safety considerations for protocol / scheduling / cycling use of LL-37: Site reactions common (peptide is cationic). Histamine-like flush possible. Caution in mast-cell-activation conditions. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

LL-37 — multifunctional antimicrobial peptide

PMID 16203862

Supporting

Cathelicidin LL-37 in immunity and inflammation

PMID 29503651

LL-37 vs Related Peptides

Compound	Profile	Onset	Best For
LL-37	Cathelicidin antimicrobial peptide	Variable; tissue-localised	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Cycle length and off-cycle period?

Standard cycle for LL-37 is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Daily timing for LL-37?

Pragmatic timing depends on pharmacokinetics: single daily dose for moderate half-life. Consistent timing matters more than the absolute clock time of any single dose.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

How do I schedule LL-37 alongside my existing stack?

LL-37's schedule is built around its Variable; tissue-localised pharmacokinetics and daily subq for 4-8 weeks dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

Should I cycle LL-37?

Standard cycle for LL-37 is 8–12 weeks of daily subq for 4-8 weeks 100-500 mcg dosing via subq/topical/nebulised, followed by a 4 week complete off-period. The off-period is calibrated to LL-37's Variable; tissue-localised half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Clinical Protocol

Start a LL-37 Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified LL-37 and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 4493 Da
Sequence length: 37 aa
Half-life: Variable; tissue-localised
WADA: Not on prohibited list
FDA: Unapproved
Research: Preclinical + small human series

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for LL-37 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for LL-37

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised